Latest Sustainable Growth News

Advanced Braking Technology Ltd reported a robust 25% revenue increase and a 36% rise in net profit for FY25, driven by international expansion and new product launches.

Advanced Braking Technology Ltd (ASX, ABV) reported a robust 25% revenue increase and 36% net profit growth for FY25, driven by international expansion and pioneering product launches in mining safety technology.

Orcoda Limited faced a challenging FY25 due to delayed projects from a key customer but is poised for recovery with new contracts and growth in recurring revenue. The company’s strategic diversification and AI-powered solutions underpin a confident outlook for FY26.

Nickel Industries reported a robust 81% rise in half-year profit to US$25.5 million, while advancing the Excelsior Nickel Cobalt project towards commissioning. The company also declared a final dividend and highlighted sustainability achievements.

Nuchev Limited reported a strong FY25 with revenue doubling to $22.9 million, driven by growth in Oli6® Nutritionals and the integration of bWellness Practitioner channel. Adjusted EBITDA loss narrowed significantly amid improved margins and cost control.

Anagenics has delivered a significant financial turnaround in FY25, driven by a strategic restructure, exiting loss-making operations, and securing new royalty agreements. Despite a revenue dip, the company improved profitability and cash flow, positioning itself for sustainable growth.

De.mem Limited has reported a record half-year performance for 2025, with revenue up 20% and its first positive adjusted EBITDA, driven by strong recurring revenues and strategic acquisitions.

Dicker Data Ltd reported a robust 15.7% increase in gross revenue for H1 FY25, driven by AI deployments and accelerated PC refresh cycles. The company also provided confident FY25 guidance amid strategic moves into AI ecosystems and cybersecurity.

Resimac Group Ltd reported a stable FY25 net profit after tax of $34.6 million and declared a fully franked final dividend of 3.5 cents per share, maintaining its steady financial footing amid modest revenue growth.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.

Beam Communications reports a pivotal FY25 marked by the divestment of its Zoleo joint venture, unlocking significant capital and delivering improved margins despite a statutory revenue decline. The company projects positive operating cash flow and growth in FY26.